![]() |
![]() |
Legal status
Patent not validated
(51) | INT.CL. | A61K 31/4422 | |
A61K 31/44 | |||
A61P 25/28 |
(11) | Number of the document | 2214666 |
(13) | Kind of document | T |
(96) | European patent application number | 08836256.1 |
Date of filing the European patent application | 2008-10-03 | |
(97) | Date of publication of the European application | 2010-08-11 |
(45) | Date of publication and mention of the grant of the patent | 2013-12-11 |
(46) | Date of publication of the claims translation |
(86) | Number | PCT/US2008/078786 |
Date | 2008-10-03 |
(87) | Number | WO 2009/046323 |
Date | 2009-04-09 |
(30) | Number | Date | Country code |
977953 P | 2007-10-05 | US | |
46109 | 2008-04-18 | US |
(72) |
MULLAN, Michael, J., US
PARIS, Daniel, US
IVEY, Robert, A., III, US
|
(73) |
Alzheimer`s Institute of America, Inc.,
7837 Parallel Parkway, Kansas City, KS 66112,
US
|
(54) | METHOD FOR REDUCING AMYLOID DEPOSITION, AMYLOID NEUROTOXICITY, AND MICROGLIOSIS WITH (-)-NILVADIPINE ENANTIOMER |
METHOD FOR REDUCING AMYLOID DEPOSITION, AMYLOID NEUROTOXICITY, AND MICROGLIOSIS WITH (-)-NILVADIPINE ENANTIOMER |